Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Amortization of Deferred Charges (2016 - 2018)

IGC Pharma (IGC) has disclosed Amortization of Deferred Charges for 8 consecutive years, with $18000.0 as the latest value for Q3 2018.

  • On a quarterly basis, Amortization of Deferred Charges fell 42.68% to $18000.0 in Q3 2018 year-over-year; TTM through Mar 2019 was $18000.0, a N/A change, with the full-year FY2019 number at $18000.0, changed N/A from a year prior.
  • Amortization of Deferred Charges was $18000.0 for Q3 2018 at IGC Pharma, up from -$115000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $63616.0 in Q3 2014 to a low of -$115000.0 in Q1 2018.
  • A 5-year average of $27604.3 and a median of $34650.0 in 2016 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: skyrocketed 356.95% in 2016, then plummeted 545.72% in 2018.
  • IGC Pharma's Amortization of Deferred Charges stood at $55200.0 in 2014, then crashed by 123.05% to -$12726.0 in 2015, then surged by 356.95% to $32700.0 in 2016, then soared by 43.73% to $47000.0 in 2017, then tumbled by 61.7% to $18000.0 in 2018.
  • Per Business Quant, the three most recent readings for IGC's Amortization of Deferred Charges are $18000.0 (Q3 2018), -$115000.0 (Q1 2018), and $47000.0 (Q4 2017).